for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
Principal Investigator
by Alain Algazi
Headshot of Alain Algazi
Alain Algazi



Expanded access for participants with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an existing clinical trial.

The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.


N/A for expanded access


Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Breast Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Other Solid Tumors With Evidence of Activating RET Alteration, Thyroid Neoplasms, Thyroid Diseases, Selpercatinib


You can join if…

Open to people ages 18 years and up

  • Diagnosis of cancer with RET activation, who are not eligible for an ongoing selpercatinib clinical trial and are medically suitable for treatment with selpercatinib
  • Have progressed or are intolerant to standard therapy, or no standard therapy option exists, or in the opinion of the investigator, are unlikely to derive significant clinical benefit from standard therapy
  • Have adequate organ function

You CAN'T join if...

  • Currently enrolled in an ongoing clinical study of selpercatinib or another RET inhibitor
  • Clinically significant active cardiovascular disease or history of myocardial infarction within 6 months prior to study treatment; ongoing cardiomyopathy; or current prolongation of the QT interval corrected for heart rate using Fridericia's formula (QTcF) interval greater than 470 milliseconds


  • UCSF not accepting new patients
    San Francisco California 94115 United States
  • City of Hope National Medical Center not accepting new patients
    Duarte California 91010-0269 United States

Lead Scientist at UCSF

  • Alain Algazi
    Dr. Alain Algazi is a specialist in medical treatment – such as chemotherapy and immunotherapy – for patients with head and neck cancers, including head and neck squamous cell carcinoma, thyroid cancers and salivary gland cancers. He leads UCSF's program in medical therapy for head and neck cancers, and chairs the head and neck cancer research committee.


not accepting new patients
Start Date
Loxo Oncology, Inc.
Study Type
Expanded Access
Last Updated